News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

25th Jul 12

Pharmaxis Announces New Board Appointment

Pharmaceutical company Pharmaxis (ASX: PXS) today announced the appointment of experienced international pharmaceutical executive Dr Simon Buckingham, to its Board of Directors. Dr Buckingham has more than 20 years experience in top tier pharmaceutical and biotechnology companies with expertise in general management, sales and marketing, clinical development, business development and corporate strategic planning.
 

 

Read full media release - pdf
25th Jun 12

Pharmaxis Welcomes Bronchitol PBS Listing Announcement

Pharmaceutical company Pharmaxis (ASX: PXS) today welcomed an announcement by the Federal government that Bronchitol will be listed on the Australian Pharmaceutical Benefits Scheme (PBS) for the treatment of cystic fibrosis.

 

Read full media release - pdf
8th Jun 12

Bronchitol Reduces Risk of Exacerbations - Additional Data

Pharmaceutical company Pharmaxis (ASX: PXS) today presented a new analysis of its two Phase 3 clinical studies of Bronchitol® showing positive trends in reducing exacerbations in all age sub groups of cystic fibrosis patients.

The analysis which focuses on adult patients, has been presented at the European Cystic Fibrosis Meeting taking place in Ireland.  Its release coincides with the commercial launch of Bronchitol in the UK and Germany following the approval by the European Medicines Agency of Bronchitol earlier this year for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care.

The two phase 3 studies contained 341 adult patients and their results were broadly consistent with those from the overall population of 600 patients which included adolescents and children.

• Adult patients who showed an increase in lung function on Bronchitol had 59% fewer exacerbations than patients who showed no improvement (p=0.03).
• Exacerbation incidence was reduced by 29% in the overall population (p=0.039) and there were consistent improvements in all age groups with a 24% reduction in adults (NS).
• Sputum weight in adult patients was significantly increased at both 6 and 14 weeks
• Lung function in adults showed significant improvements over the 6 months of the study and were sustained out to 12 months. 
• For adults, there was no increase in treatment burden after taking Bronchitol for 6 months.

 

Read full media release - pdf